ライフサイエンスコーパス: Clostridium difficile infection

1 idian Bioscience, Inc.) for the diagnosis of Clostridium difficile infection.

2 bleed, ventilator-associated pneumonia, and Clostridium difficile infection.

3 those at high risk of complications such as Clostridium difficile infection.

4 onia, ICU mortality, ICU length of stay, and Clostridium difficile infection.

5 ) in an investigation of the transmission of Clostridium difficile infection.

6 n of outbreaks is crucial for the control of Clostridium difficile infection.

7 and fidaxomicin are therapies of choice for Clostridium difficile infection.

8 n was recently approved for the treatment of Clostridium difficile infection.

9 aboratories from utilizing real-time PCR for Clostridium difficile infection.

10 ce, severity, and high rate of recurrence of Clostridium difficile infection.

11 mples for CCCA did not increase detection of Clostridium difficile infection.

12 G II plays in the rabbit ileal-loop model of Clostridium difficile infection.

13 ns about promoting antibiotic resistance and Clostridium difficile infection.

14 nsecutive, evaluable patients with recurrent Clostridium difficile infection.

15 mycin antibiotic treatment and opportunistic Clostridium difficile infection.

16 contributes to the pathology observed during Clostridium difficile infection.

17 antimicrobial use and adverse events such as Clostridium difficile infections.

18 r understanding the changing epidemiology of Clostridium difficile infections.

19 , ventilator-associated pneumonia (VAP), and Clostridium difficile infections.

20 zole: 2), and one patient was diagnosed with Clostridium difficile infection (0 vs 1).

21 ently encountered infectious etiologies were Clostridium difficile infection (13.3% and 11.8%, respec

22 Clostridium difficile infection after LT was associated

23 ts it has been successfully used in cases of Clostridium difficile infection and IBD, although contro

24 We also assessed rates of Clostridium difficile infection and potential allergic r

25 al microbiota transplantation to face severe Clostridium difficile infections and to perform decoloni

26 ated charges for inflammatory bowel disease, Clostridium difficile infection, and chronic liver disea

27 with outcomes (antibiotic-days, incidence of Clostridium difficile infection, and in-hospital mortali

28 han 9000 nosocomial infections, 1000 to 5000 Clostridium difficile infections, and 2 to 6 cases of an

29 ctors affecting a person's susceptibility to Clostridium difficile infection are well-understood, lit

30 The symptoms of Clostridium difficile infections are caused by two exoto

31 tic withdrawal regimen may resolve recurrent Clostridium difficile infection as effectively as fecal

32 sistently toxin-negative patients tested for Clostridium difficile infection between February 1998 an

33 We identified 12 patients with Clostridium difficile infection between July 2011 and Ma

34 s is not observed in subjects with recurrent Clostridium difficile infection but is observed in the s

35 rded as the primary virulence determinant in Clostridium difficile infection, but naturally occurring

36 ffective in treating relapsing or refractory Clostridium difficile infection, but practical barriers

37 cottish government issued a target to reduce Clostridium difficile infection by 30% in 2 years.

38 For 139 patients tested for Clostridium difficile infection by polymerase chain reac

39 Variations in testing for Clostridium difficile infection can hinder patients' car

40 Clostridium difficile infection can result in asymptomat

41 Clostridium difficile infection causes severe complicati

42 The incidence of Clostridium difficile infection (CDI) and associated mor

43 plification tests (NAATs) do not distinguish Clostridium difficile infection (CDI) and asymptomatic C

44 e advances in the diagnosis and treatment of Clostridium difficile infection (CDI) and prevention eff

45 Nonsevere Clostridium difficile infection (CDI) and severe CDI, wh

46 n to be noninferior to vancomycin for curing Clostridium difficile infection (CDI) and superior for r

47 f reduced response to standard therapies for Clostridium difficile infection (CDI) and the risk for r

48 Obesity and Clostridium difficile infection (CDI) are both related t

49 es suggest that most cases of hospital-onset Clostridium difficile infection (CDI) are unrelated to o

50 methods may underestimate the true burden of Clostridium difficile infection (CDI) because they fail

51 Prevention and management of Clostridium difficile infection (CDI) can be improved by

52 Clostridium difficile infection (CDI) can cause a wide r

53 Clostridium difficile infection (CDI) can cause severe d

54 Clostridium difficile infection (CDI) causes nearly half

55 tic increase in morbidity and mortality from Clostridium difficile infection (CDI) due to the recent

56 The dramatic changes in the epidemiology of Clostridium difficile infection (CDI) during recent year

57 Little is known about pediatric Clostridium difficile infection (CDI) epidemiology.

58 Isolates from consecutive Clostridium difficile infection (CDI) fecal samples unde

59 Clostridium difficile infection (CDI) following antibiot

60 Recurrent or refractory Clostridium difficile infection (CDI) has become an incr

61 Clostridium difficile infection (CDI) has become one of

62 dences of antibiotic-associated diarrhea and Clostridium difficile infection (CDI) has been demonstra

63 The incidence of Clostridium difficile infection (CDI) has been increasin

64 icrobiota transplantation (FMT) in recurrent Clostridium difficile infection (CDI) has been limited t

65 igh sensitivity of PCR assays for diagnosing Clostridium difficile infection (CDI) has greatly reduce

66 splantation (FMT) as treatment for recurrent Clostridium difficile infection (CDI) has increased rapi

67 osing to, or modulating disease severity in, Clostridium difficile infection (CDI) has not been inves

68 The incidence of Clostridium difficile infection (CDI) has risen almost 3

69 The incidence of Clostridium difficile infection (CDI) has risen dramatic

70 Patients with recurrent Clostridium difficile infection (CDI) have a >/=60% risk

71 The incidence and severity of Clostridium difficile infection (CDI) have increased wor

72 Since 2000, the incidence and severity of Clostridium difficile infection (CDI) have increased.

73 The currently available diagnostics for Clostridium difficile infection (CDI) have major limitat

74 id suppression medication is associated with Clostridium difficile infection (CDI) in adults and is i

75 ent approved by the FDA for the treatment of Clostridium difficile infection (CDI) in adults over the

76 dies on risk factors for and transmission of Clostridium difficile infection (CDI) in China have been

77 This article defines the risk factors for Clostridium difficile infection (CDI) in hospitalized ch

78 Rates and severity of Clostridium difficile infection (CDI) in hospitals in No

79 The increased incidence and severity of Clostridium difficile infection (CDI) in older adults (a

80 e clinical and laboratory characteristics of Clostridium difficile infection (CDI) in patients with d

81 Clostridium difficile infection (CDI) incidence has incr

82 and influenza are associated with nosocomial Clostridium difficile infection (CDI) incidence, but the

83 Marked increases in Clostridium difficile infection (CDI) incidence, driven

84 Clostridium difficile infection (CDI) is a common and in

85 Clostridium difficile infection (CDI) is a common compli

86 Clostridium difficile infection (CDI) is a frequent comp

87 Clostridium difficile infection (CDI) is a growing conce

88 Clostridium difficile infection (CDI) is a leading cause

89 Clostridium difficile infection (CDI) is a leading cause

90 Clostridium difficile infection (CDI) is a leading cause

91 Clostridium difficile infection (CDI) is a major burden

92 Clostridium difficile infection (CDI) is a major cause o

93 Clostridium difficile infection (CDI) is a serious compl

94 Prevention of recurrent Clostridium difficile infection (CDI) is a substantial t

95 Clostridium difficile infection (CDI) is an important ca

96 Clostridium difficile infection (CDI) is an important ho

97 Clostridium difficile infection (CDI) is associated with

98 Clostridium difficile infection (CDI) is associated with

99 Clostridium difficile infection (CDI) is common after li

100 Clostridium difficile infection (CDI) is facilitated by

101 Mortality among patients with Clostridium difficile infection (CDI) is high.

102 The incidence of Clostridium difficile infection (CDI) is increasing, eve

103 mal therapy for critically ill patients with Clostridium difficile infection (CDI) is not known.

104 f fecal microbiota transplantation (FMT) for Clostridium difficile infection (CDI) is not well-known.

105 Recurrent Clostridium difficile infection (CDI) is of particular c

106 Clostridium difficile infection (CDI) is one of the most

107 Clostridium difficile infection (CDI) is the leading hea

108 Clostridium difficile infection (CDI) is the most common

109 Clostridium difficile infection (CDI) is the most common

110 The success of FMT in curing Clostridium difficile infection (CDI) is well establishe

111 Recurrence of Clostridium difficile infection (CDI) occurs in approxim

112 Symptomatic recurrence of Clostridium difficile infection (CDI) occurs in approxim

113 Recurrent Clostridium difficile infection (CDI) occurs in up to 35

114 Patients with suspected Clostridium difficile infection (CDI) often receive empi

115 The impact of Clostridium difficile infection (CDI) on healthcare is b

116 gel electrophoresis type 1 (NAP1) strain in Clostridium difficile infection (CDI) outcome.

117 Managing recurrent Clostridium difficile infection (CDI) presents a signifi

118 Clostridium difficile infection (CDI) ranges from asympt

119 Variation in Clostridium difficile infection (CDI) rates between heal

120 This study analyzes and reports Clostridium difficile infection (CDI) rates, risk factor

121 innate immune response to the resolution of Clostridium difficile infection (CDI) remains incomplete

122 Clostridium difficile infection (CDI) represents an impo

123 Clostridium difficile infection (CDI) represents the mos

124 Clostridium difficile infection (CDI) results in toxin-i

125 Clostridium difficile infection (CDI) seems to be changi

126 Most Clostridium difficile infection (CDI) surveillance progr

127 of anaerobic microbiota during treatment of Clostridium difficile infection (CDI) than vancomycin an

128 Treatment of recurrent Clostridium difficile infection (CDI) with antibiotics l

129 Recurrent Clostridium difficile infection (CDI) with poor response

130 are few high-quality studies of the costs of Clostridium difficile infection (CDI), and the majority

131 iable option for the treatment of refractory Clostridium difficile infection (CDI), and, more recentl

132 for the efficacy of probiotics in preventing Clostridium difficile infection (CDI), but guidelines do

133 (FT) is a promising treatment for recurrent Clostridium difficile infection (CDI), but its true effe

134 polymorphism rs4073/-251T >A predisposes to Clostridium difficile infection (CDI), but this associat

135 catheter-associated urinary tract infection, Clostridium difficile infection (CDI), central line-asso

136 oratory tests are available for diagnosis of Clostridium difficile infection (CDI), delays in complet

137 effective alternative therapy for recurrent Clostridium difficile infection (CDI), is infrequently u

138 Unfortunately, the rise of Clostridium difficile infection (CDI), particularly in e

139 During treatment of Clostridium difficile infection (CDI), patterns of patho

140 Clostridium difficile infection (CDI), the most common h

141 es have evaluated risk factors for recurrent Clostridium difficile infection (CDI), the vast majority

142 ens, including acute kidney injury (AKI) and Clostridium difficile infection (CDI), were also conside

143 peutic effects of dietary supplementation on Clostridium difficile infection (CDI).

144 s (NAATs) as the primary diagnostic test for Clostridium difficile infection (CDI).

145 increasingly being adopted for diagnosis of Clostridium difficile infection (CDI).

146 nd multitest algorithms for the diagnosis of Clostridium difficile infection (CDI).

147 on approved fidaxomicin for the treatment of Clostridium difficile infection (CDI).

148 -Counterpoint on the laboratory diagnosis of Clostridium difficile infection (CDI).

149 pt of antibiotics is a major risk factor for Clostridium difficile infection (CDI).

150 recently been approved for the treatment of Clostridium difficile infection (CDI).

151 mg twice per day for 10 days as treatment of Clostridium difficile infection (CDI).

152 collected from patients suspected of having Clostridium difficile infection (CDI).

153 considered important for protection against Clostridium difficile infection (CDI).

154 rope and the United States for patients with Clostridium difficile infection (CDI).

155 e to severe disease and treatment failure in Clostridium difficile infection (CDI).

156 is a highly effective therapy for recurrent Clostridium difficile infection (CDI).

157 is a highly effective therapy for recurrent Clostridium difficile infection (CDI).

158 ease states, and the prototypical example is Clostridium difficile infection (CDI).

159 he gastrointestinal microbiome to facilitate Clostridium difficile infection (CDI).

160 Clostridium difficile infections (CDI) are a growing con

161 Renewed interest in Clostridium difficile infections (CDI) is stimulating re

162 n to form the vegetative cells that initiate Clostridium difficile infections (CDI).

163 ed hospitalization, and hospitalization with Clostridium difficile infection [CDI]) were associated w

164 BACKGROUND & AIMS: Studies of Clostridium difficile infections (CDIs) among individual

165 (IRR 0.79; 95% CI, 0.67-0.92; P = .004) and Clostridium difficile infections (CDIs; IRR 0.46; 95% CI

166 The diagnosis of Clostridium difficile infection continues to be a challe

167 viously used to cure patients with recurrent Clostridium difficile infection, could also protect agai

168 biotic-based strategies for the treatment of Clostridium difficile infections disrupt indigenous micr

169 The epidemic of Clostridium difficile infection fueled by new virulent s

170 den of antimicrobial-resistant organisms and Clostridium difficile infections, halting unnecessary an

171 The incidence of Clostridium difficile infection has increased among chil

172 Clostridium difficile infection has increased in inciden

173 The prevalence of Clostridium difficile infections has increased due to th

174 Hospitalizations and mortality from Clostridium difficile infection have doubled in the last

175 Numbers of Clostridium difficile infections have increased worldwid

176 The global prevalence of severe Clostridium difficile infection highlights the profound

177 h care-onset health care facility-associated Clostridium difficile infection (HO-CDI) is overdiagnose

178 actam (PIP/TAZO) shortage and hospital-onset Clostridium difficile infection (HO-CDI) risk in 88 US m

179 vancin was more effective than vancomycin in Clostridium difficile infection in hamsters.

180 Clostridium difficile infection in LT recipients was ass

181 We compared rates of recurrent Clostridium difficile infection in patients receiving or

182 The detection and diagnosis of Clostridium difficile infection in pediatric populations

183 recognition of several serious outbreaks of Clostridium difficile infection in the industrialized wo

184 The magnitude and scope of Clostridium difficile infection in the United States con

185 The occurrence of Clostridium difficile infections in patients that do not

186 antations for different disorders, including Clostridium difficile infection, irritable bowel syndrom

187 Clostridium difficile infection is a growing problem in

188 Clostridium difficile infection is a leading cause of an

189 common misconceptions lead to misdiagnosis: Clostridium difficile infection is a possibility when th

190 Clostridium difficile infection is a relatively common n

191 Clostridium difficile infection is a serious and highly

192 Clostridium difficile infection is almost unrecognized i

193 eudomembranous enterocolitis associated with Clostridium difficile infection is an important cause of

194 Clostridium difficile infection is an increasing burden

195 om recent experiments on antibiotic-mediated Clostridium difficile infection is analyzed to quantify

196 Clostridium difficile infection is associated with broad

197 Disease associated with Clostridium difficile infection is caused by the actions

198 Diagnosis of Clostridium difficile infection is controversial because

199 Recurrent Clostridium difficile infection is difficult to treat, a

200 Clostridium difficile infection is increasing in inciden

201 Colonic inflammation in Clostridium difficile infection is mediated by released

202 Their use as probiotics for prevention of Clostridium difficile infection is prevalent among consu

203 Clostridium difficile infection is the leading cause of

204 Clostridium difficile infection is the leading cause of

205 Clostridium difficile infection is the leading cause of

206 Clostridium difficile infection is the main cause of hea

207 Clostridium difficile infection is the most common cause

208 Clostridium difficile infection is the most common healt

209 It has been thought that Clostridium difficile infection is transmitted predomina

210 Of most import is the realization that Clostridium difficile infection is ubiquitous and must b

211 The control of Clostridium difficile infections is an international cli

212 or-associated complication or pneumonia, and Clostridium difficile infection; minor outcomes included

213 1), and grade 3 diarrhea in the presence of Clostridium difficile infection (n = 1).

214 mine whether the reductions in recurrence of Clostridium difficile infection observed with fidaxomici

215 Clostridium difficile infection occurred in 27 (14%) of

216 pment for therapy of systemic infections and Clostridium difficile infection of the gastrointestinal

217 Clostridium difficile infection often occurred soon afte

218 reports found addressed the use of FMTs for Clostridium difficile infection or inflammatory bowel di

219 for the same infection, acute kidney injury, Clostridium difficile infection, or drug-related adverse

220 with their use including increased risk for Clostridium difficile infection, pneumonia, and fracture

221 Recurrent Clostridium difficile infection (RCDI) is associated wit

222 utic modality for the treatment of recurrent Clostridium difficile infection (RCDI).

223 tinal flora with resultant cure of recurrent Clostridium difficile infection (RCDI).

224 ast 50 years for the treatment of refractory Clostridium difficile infections (RCDIs) in adults, it h

225 py, and frequency of complications including Clostridium difficile infection, readmission, and all-ca

226 le in developing the IDSA/SHEA guidelines on Clostridium difficile infection (see Wilcox and Planche'

227 Clostridium difficile infection should be ruled out, as

228 treatment of portal systemic encephalopathy, Clostridium difficile infection, small bowel intestinal

229 Whereas many antibiotics increase risk of Clostridium difficile infection through dysbiosis, epide

230 treated population, the overall incidence of Clostridium difficile infection was 1.7% in the ertapene

231 Rates of nosocomial Clostridium difficile infection were compared by using i

232 ation (FMT) is effective in the treatment of Clostridium difficile infection, where efficacy correlat

233 fective for treating patients with recurrent Clostridium difficile infection who are left with few cl

234 cohort of 109 subjects treated for recurrent Clostridium difficile infection with fecal microbiota tr

235 t serious cephalosporin-associated ADRs were Clostridium difficile infection within 90 days (0.91%),

236 acious and inexpensive therapy for recurrent Clostridium difficile infection, yet its safety is thoug